HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at Cantor Fitzgerald's Inaugural Healthcare Conference on Wednesday, July 8 at 4:45 p.m. Eastern Time, at the Le Parker Meridian Hotel in New York, NY.
A webcast will be available during the presentation and may be accessed through the BrainStorm Cell Therapeutics website or directly at http://wsw.com/webcast/cantor2/bcli. The webcast will be archived and available at that site for 90 days.
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
SOURCE BrainStorm Cell Therapeutics Inc.